Anthera Pharmaceuticals, Inc. ANTH

ANTH Company Overview

Anthera Pharmaceuticals, Inc. was a U.S.-based biopharmaceutical company focused on developing therapies for inflammatory diseases and unmet medical needs in immunology. The company operated within the biotechnology and specialty pharmaceutical industries, with its primary efforts centered on developing novel protein and peptide-based therapeutics. Its lead development programs historically included blisibimod for systemic lupus erythematosus (SLE) and Sollpura, a pancreatic enzyme replacement therapy intended for exocrine pancreatic insufficiency associated with cystic fibrosis.

The company was founded in 2004 and was headquartered in Hayward, California. Anthera pursued a clinical-stage development model rather than a commercial pharmaceutical model, relying primarily on capital raised through public equity offerings and strategic licensing arrangements rather than recurring product sales. Public filings and historical investor disclosures indicate that the company experienced significant clinical and financial setbacks following unsuccessful late-stage trial outcomes, which materially affected its operations and long-term viability. Data regarding ongoing active operations after its delisting and restructuring activities is inconclusive based on available public sources.